David F. Penson

David F. Penson's AcademicInfluence.com Rankings

David F. Penson

Medical

#1771

World Rank

#2147

Historical Rank

Urology

World Rank

#10

Historical Rank

medical Degrees

David F. Penson

Philosophy

#5319

World Rank

#8081

Historical Rank

Logic

#2620

World Rank

#3636

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is David F. Penson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David F. Penson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) (4808)
Early detection of prostate cancer: AUA Guideline. (2013) (1061)
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (1026)
Update on AUA guideline on the management of benign prostatic hyperplasia. (2011) (1018)
Overdiagnosis and overtreatment of prostate cancer. (2014) (728)
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. (2002) (711)
Epidemiology and cost of ventral hernia repair: making the case for hernia research (2012) (696)
Prostate Cancer, Version 1.2016. (2016) (586)
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. (2005) (564)
Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015) (562)
Nationwide trends in mastectomy for early-stage breast cancer. (2015) (518)
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. (2004) (500)
Quantifying the role of PSA screening in the US prostate cancer mortality decline (2008) (391)
Long-term functional outcomes after treatment for localized prostate cancer. (2013) (364)
Prostate cancer and the Will Rogers phenomenon. (2005) (319)
Castration-resistant prostate cancer: AUA Guideline. (2013) (273)
Why do men choose one treatment over another? (2006) (269)
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. (2016) (265)
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years (2017) (263)
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. (2013) (231)
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. (2007) (224)
Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. (2003) (223)
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. (2005) (221)
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. (2021) (201)
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. (2003) (200)
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. (2013) (189)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. (2020) (185)
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. (2008) (176)
Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer (2013) (161)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. (2001) (156)
Quality of life after breast cancer diagnosis and survival. (2011) (149)
Health-related quality of life in men with prostate cancer. (2003) (146)
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. (2010) (144)
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. (2007) (140)
Determining cause of death in prostate cancer: are death certificates valid? (2001) (134)
Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. (1996) (134)
Health related quality of life for men treated for localized prostate cancer with long-term followup. (2010) (131)
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. (2006) (130)
Evaluating localized prostate cancer and identifying candidates for focal therapy. (2008) (129)
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. (2020) (122)
Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. (2015) (121)
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. (2007) (120)
Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. (2015) (118)
Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. (2001) (117)
Epidemiology of Stress Urinary Incontinence in Women (2011) (117)
The effectiveness of screening for prostate cancer: a nested case-control study. (2006) (115)
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. (2008) (115)
Cigarette smoking and risk of prostate cancer in middle-aged men. (2003) (112)
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. (2005) (108)
The prostate cancer conundrum revisited (2012) (104)
Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. (2010) (103)
Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach (2008) (101)
The hemodynamic pathophysiology of impotence following blunt trauma to the erect penis. (1992) (100)
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. (2011) (100)
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. (2012) (100)
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. (2004) (99)
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. (2013) (97)
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? (2013) (94)
Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. (2008) (94)
Renal cell cancer histological subtype distribution differs by race and sex (2016) (94)
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer (2016) (94)
Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. (2013) (91)
Internet Health Resources and the Cancer Patient (2008) (91)
The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. (2013) (89)
Trends in the treatment of localized prostate cancer using supplemented cancer registry data (2011) (87)
Survivorship and improving quality of life in men with prostate cancer. (2015) (86)
Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. (2002) (85)
The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates (2011) (85)
Recent Changes in Prostate Cancer Screening Practices and Epidemiology (2017) (82)
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. (2011) (82)
Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. (2011) (81)
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. (2004) (81)
Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. (2017) (80)
Patient-reported outcome measures in dysphagia: a systematic review of instrument development and validation. (2017) (80)
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. (2015) (79)
Epidemiology of Vocal Fold Paralyses after Total Thyroidectomy for Well-Differentiated Thyroid Cancer in a Medicare Population (2014) (78)
Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. (2017) (76)
Prostate cancer on the Internet--information or misinformation? (2006) (75)
How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. (2002) (75)
Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. (2006) (73)
Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. (2009) (72)
Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. (2007) (71)
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. (2019) (70)
Differences in health‐related quality of life of prostate cancer patients based on stage of cancer (2004) (70)
Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. (2003) (69)
Cross‐sectional and longitudinal comparisons of health‐related quality of life between patients with prostate carcinoma and matched controls (2004) (69)
The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer (2014) (68)
Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. (2004) (68)
The cost-effectiveness of treatment for varicocele related infertility. (2002) (67)
Checklist to operationalize measurement characteristics of patient-reported outcome measures (2016) (65)
Volume outcomes of cystectomy--is it the surgeon or the setting? (2012) (65)
Prostate Cancer Registries: Current Status and Future Directions. (2016) (64)
Urinary diversion: how experts divert. (2015) (64)
Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. (2009) (64)
Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. (2012) (64)
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy (2014) (62)
Obesity, body composition, and prostate cancer (2012) (61)
Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. (2013) (61)
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. (2005) (60)
Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer (2008) (60)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (59)
Hospital-Physician Consolidation Accelerated In The Past Decade In Cardiology, Oncology. (2018) (59)
A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III) (2019) (58)
What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models (2011) (57)
Increasing use of observation among men at low risk for prostate cancer mortality. (2015) (57)
Voice-Related Patient-Reported Outcome Measures: A Systematic Review of Instrument Development and Validation. (2017) (57)
Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. (2012) (57)
Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. (1999) (56)
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. (2011) (55)
Quality of life after treatment for prostate cancer (2003) (55)
Association between race and follow‐up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial (2013) (55)
The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. (2016) (55)
Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial (2008) (54)
Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. (2011) (54)
Effectiveness of Hormonal and Surgical Therapies for Cryptorchidism: A Systematic Review (2013) (54)
On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. (2007) (53)
Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. (2005) (53)
Laparoscopic partial nephrectomy and prostatectomy: weighing the costs and the benefits. (2004) (52)
Provider and partner interactions in the treatment decision‐making process for newly diagnosed localized prostate cancer (2011) (50)
The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. (2012) (50)
Trends in Treatment Costs for Localized Prostate Cancer: The Healthy Screenee Effect (2007) (49)
Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients (2016) (49)
The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy (2016) (49)
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer (2019) (47)
Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. (2003) (47)
Invasive T1 bladder cancer: indications and rationale for radical cystectomy (2008) (46)
Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment (2014) (46)
Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate‐specific antigen (2015) (46)
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. (2006) (46)
Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap (2010) (46)
Pelvic organ prolapse (POP) surgery: the evidence for the repairs (2011) (45)
Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial (2019) (45)
Preliminary treatment considerations among men with newly diagnosed prostate cancer. (2010) (44)
The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3‐Year Results from the CEASAR Study (2017) (44)
Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. (2012) (44)
Adrenal control of erectile function and nitric oxide synthase in the rat penis. (1997) (43)
Racial variation in the quality of surgical care for bladder cancer (2014) (43)
Patient-Reported Outcome Measures Related to Laryngopharyngeal Reflux (2016) (43)
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective (2013) (43)
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions (2011) (42)
Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. (2008) (42)
An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. (2004) (41)
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? (2004) (41)
The physical burden of prostate cancer. (2003) (41)
Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. (2009) (41)
Quality of Life After Therapy for Localized Prostate Cancer (2007) (41)
Centralization of radical prostatectomy in the United States. (2013) (40)
Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. (2014) (40)
Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. (2003) (40)
Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. (2013) (40)
Combining longitudinal studies of PSA. (2004) (39)
Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity (2011) (38)
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) (2013) (38)
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. (2005) (38)
Early prostate cancer: prevention, treatment modalities, and quality of life issues. (2003) (38)
A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy (2015) (37)
Factors influencing patients' acceptance and adherence to active surveillance. (2012) (37)
Knowledge of the harms of tobacco use among patients with bladder cancer (2014) (37)
Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. (2012) (37)
Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. (2001) (37)
Evaluation and Treatment of Cryptorchidism (2012) (37)
Magnetic Resonance Imaging for Locating Nonpalpable Undescended Testicles: A Meta-analysis (2013) (37)
Assessment of patient experience with unilateral vocal fold immobility: a preliminary study. (2014) (37)
Short term complications from transurethral resection of bladder tumor. (2016) (37)
Surgeon Participation in Early Accountable Care Organizations (2017) (36)
The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients (2012) (36)
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries (2013) (35)
Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. (2002) (35)
Erectile Dysfunction in Diabetic Patients (2004) (35)
Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. (2015) (35)
Prostate cancer: epidemiology and health-related quality of life. (2008) (34)
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. (2010) (34)
The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. (2005) (34)
Erectile aid use by men treated for localized prostate cancer. (2009) (34)
Review Article HEALTH RELATED QUALITY OF LIFE IN MEN WITH PROSTATE CANCER (2003) (34)
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts (2018) (34)
Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. (2015) (34)
Urinary functional outcomes in female neobladder patients (2014) (34)
Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. (2009) (32)
Association Between Socioeconomic Status (SES) and Lower Urinary Tract Symptom (LUTS) Severity Among Black and White Men (2011) (32)
Racial variation in the quality of surgical care for prostate cancer. (2012) (31)
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. (2018) (31)
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. (2013) (31)
Access to information sources and treatment considerations among men with local stage prostate cancer. (2009) (31)
The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. (2001) (30)
Effect of injection augmentation on need for framework surgery in unilateral vocal fold paralysis (2016) (30)
Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study (2015) (30)
Male Sexual Function: A Guide to Clinical Management (2002) (30)
Quality of life in patients with localized prostate cancer. (2005) (30)
Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. (2014) (29)
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. (2004) (29)
Trends in the use of evidence‐based therapy for resectable gastric cancer (2014) (28)
Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy. (2014) (27)
Gender, Race, and Variation in the Evaluation of Microscopic Hematuria Among Medicare Beneficiaries (2015) (27)
Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsement. (2015) (27)
Clinical research methods for surgeons (2007) (26)
Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. (2006) (26)
Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States. (2002) (26)
The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. (2019) (25)
Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. (2021) (25)
Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening (2018) (24)
Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. (2021) (24)
Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. (2002) (24)
Long‐term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy (2011) (24)
Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study (2011) (23)
Re: optimization of PSA screening policies: a comparison of the patient and societal perspectives. (2013) (23)
Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. (2006) (23)
Quality of life with advanced metastatic prostate cancer. (2012) (22)
Re: Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. (2016) (22)
Quality of life after treatment for prostate cancer (2003) (22)
The Pendulum of Prostate Cancer Screening. (2015) (22)
Diffusion of surgical innovation among patients with kidney cancer (2008) (22)
Re: Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia (2011) (22)
Successful external validation of a model to predict other cause mortality in localized prostate cancer (2016) (22)
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. (2007) (21)
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population (2011) (21)
Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer (2017) (21)
Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer (2017) (21)
Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. (2016) (21)
The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. (2015) (20)
Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. (2004) (20)
Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. (2016) (20)
Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. (2017) (20)
Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis (2003) (20)
Prevention of seminiferous tubular atrophy in a naturally cryptorchid rat model by early surgical intervention. (1996) (19)
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. (2017) (19)
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study (2017) (18)
The Power and the Peril of Large Administrative Databases. (2015) (18)
Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? (2005) (18)
The Patient Protection and Affordable Care Act: the impact on urologic cancer care. (2013) (18)
Urinary retention and catheter use among U.S. female Medicare beneficiaries: Prevalence and risk factors (2017) (17)
Prostate cancer. (2007) (17)
AUA/Optimal Techniques of Prostate Biopsy and Specimen Handling (2013) (17)
The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. (2017) (17)
Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer (2018) (17)
Therapeutic Ultrasound and Prostate Cancer (2017) (16)
An update on randomized clinical trials in localized and locoregional prostate cancer. (2005) (16)
Treatment outcomes in localized prostate cancer: a patient-oriented approach. (2002) (16)
Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. (2020) (16)
TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. (2017) (16)
Patterns and predictors of urodynamics use in the United States. (2013) (16)
Assessing the quality of prostate cancer care (2008) (16)
Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis (2008) (15)
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (15)
Patient-Reported Outcome Measures in Upper Airway–Related Dyspnea: A Systematic Review (2017) (15)
Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. (2014) (15)
Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. (1997) (14)
MRI-guided transurethral ultrasound ablation of prostate cancer. (2020) (14)
Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications (2016) (14)
Segmental testicular infarction in the neonate: a case report. (1995) (14)
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. (2013) (13)
A randomized trial of a specialist palliative care intervention for patients undergoing surgery for cancer: rationale and design of the Surgery for Cancer with Option of Palliative Care Expert (SCOPE) Trial (2019) (13)
The politics of prostate cancer screening. (2014) (13)
Bone Complications Among Prostate Cancer Survivors: Long-Term Follow-Up From the Prostate Cancer Outcomes Study (2014) (13)
Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer. (2012) (13)
Decision‐making processes among men with low‐risk prostate cancer: A survey study (2018) (13)
Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. (2013) (12)
Choledocholithiasis management in rural America: health disparity or health opportunity? (2011) (12)
Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. (2015) (12)
Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. (2020) (12)
Letters to the Editor/Errata Re: Early Detection of Prostate Cancer: AUA guideline (2013) (11)
The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening (2018) (11)
Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. (2014) (10)
Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. (2018) (10)
Current Perspective on Adverse Effects in Shock Wave Lithotripsy (2009) (10)
Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: an Underutilized Strategy (2013) (10)
8: Predictors of HRQOL Duirng Long-Term Follow-Up of Men Treated for Prostate Cancer (2007) (10)
Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. (2010) (10)
Re: The Correlation of Media Ranking’s “Best” Hospitals and Surgical Outcomes following Radical Cystectomy for Urothelial Cancer (2015) (10)
More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades (2017) (10)
Racial variation in receipt of quality radiation therapy for prostate cancer (2018) (9)
Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer (2019) (9)
COVID-19 and financial toxicity in patients with renal cell carcinoma (2020) (9)
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. (2012) (9)
Canadian Consensus Conference: The FDA decision on the use of 5ARIs. (2012) (9)
Computer-generated graphical presentations: use of multimedia to enhance communication. (1997) (9)
Comparative effectiveness research in localized prostate cancer treatment. (2013) (9)
Active surveillance: not your father's watchful waiting. (2009) (9)
Future Research Needs for Outcomes of Weight Gain in Pregnancy (2010) (9)
Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. (2019) (8)
Cost-effective management of pelvic fracture urethral injuries (2017) (8)
Effect of Age, Tumor Risk, and Comorbidity in a U.S. Population–Based Cohort of Men With Prostate Cancer (2013) (8)
Trends in urodynamics in U.S. female medicare beneficiaries, 2000–2010 (2015) (8)
Quality of life following prostate cancer treatments (2000) (8)
Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer (2010) (8)
Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: a cost-minimization analysis. (2012) (8)
Outpatient versus Inpatient Observation after Percutaneous Native Kidney Biopsy: A Cost Minimization Study (2011) (8)
Patient-Reported Outcome Measures in Colon and Rectal Surgery: A Systematic Review and Quality Assessment (2020) (8)
Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study. (2018) (7)
Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? (2019) (7)
Health care reform 2010: a fresh view on tort reform. (2010) (7)
Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer (2012) (7)
OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL‐T: PRELIMINARY DATA FROM THE PROCEED REGISTRY: PD24‐12 (2017) (7)
Re: National Health Expenditure Projections, 2013-23: Faster Growth Expected with Expanded Coverage and Improving Economy. (2015) (7)
Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. (2019) (6)
The Effectiveness of Screening for Prostate Cancer (2002) (6)
Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. (2018) (6)
Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice (2015) (6)
Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts (2020) (6)
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. (2019) (6)
What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study (2020) (6)
Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease (2022) (6)
PROSTATE CANCER DETECTION USING A NOVEL COMPUTERIZED THREE-DIMENSIONAL PROSTATE BIOPSY TEMPLATE (TARGETSCAN™): RESULTS OF A MULTICENTER PROSPECTIVE DATA REGISTRY (2009) (6)
Fibromyxoid Nephrogenic Adenoma in the Ureter (2018) (6)
An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival (2017) (6)
National Variation in Elective Colon Resection for Diverticular Disease (2020) (5)
686 SURVIVAL OUTCOMES FOLLOWING SURGERY OR RADIATION FOR LOCALIZED PROSTATE CANCER RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY (2012) (5)
913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer (2005) (5)
Leapfrog volume thresholds and perioperative complications after radical prostatectomy. (2013) (5)
Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening. (2016) (5)
Modeling economic and epidemiological impact of voluntary medical male circumcision among men who have sex with men in Beijing, China (2019) (5)
Physicians’ perspectives on the informational needs of low-risk prostate cancer patients (2017) (5)
Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right? (2018) (5)
Post-prostatectomy incontinence and pelvic floor muscle training: a defining problem. (2013) (5)
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research (2016) (5)
Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients (2008) (5)
Re: Changes in Burnout and Satisfaction with Work-Life Balance in Physicians and the General US Working Population between 2011 and 2014. (2016) (5)
The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer (2014) (4)
Re: association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. (2014) (4)
Socioeconomic factors, urological epidemiology and practice patterns. (2010) (4)
Evaluation and Treatment of Cryptorchidism [Internet] (2012) (4)
Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study (2008) (4)
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy (2019) (4)
Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. (2008) (4)
Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. (2019) (4)
Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes (2022) (4)
PII-LBA10 A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER (CRPC): THE STRIVE TRIAL (2015) (4)
Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. (2020) (4)
Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013-4. (2016) (4)
LBA20 MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) IN PATIENTS WITH LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS OF TACT PIVOTAL STUDY (2018) (4)
Re: Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. (2013) (4)
Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data? (2005) (4)
Age at surgery for undescended testis and risk of testicular cancer (2007) (4)
28: The Cost-Effectiveness of Combined Androgen Blockade with Bicalutamide and LHRH Agonist in Men with Stage D2 Prostate Cancer (2005) (4)
Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. (2020) (4)
Adhering to the standard of care for prostate cancer. (2012) (4)
The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. (2011) (4)
Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study. (2018) (4)
Outcomes research in urology (2011) (4)
The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. (2020) (4)
Patient expectations of benefit from systemic treatments for metastatic prostate cancer (2019) (4)
Re: variation in surgical-readmission rates and quality of hospital care. (2014) (3)
The influence of provider characteristics and market forces on response to financial incentives. (2017) (3)
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. (2020) (3)
Validation of a staging system for evaluating prognosis in prostate cancer. (1998) (3)
Five‐year outcomes from a prospective comparative effectiveness study evaluating external‐beam radiotherapy with or without low‐dose‐rate brachytherapy boost for localized prostate cancer (2021) (3)
Medicare reimbursement changes for bladder biopsies (2010) (3)
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. (2016) (3)
Re: Exploring the Burden of Inpatient Readmissions after Major Cancer Surgery. (2015) (3)
Re: urologists' use of intensity-modulated radiation therapy for prostate cancer. (2014) (3)
IMPACT OF RACE, COMORBIDITIES, PERCEPTION OF GENERAL HEALTH AND RISK CLASSIFICATION ON THE TYPE OF TREATMENT IN MEN WITH PROSTATE CANCER: CAPSURE DATA (2009) (3)
Anticipating the Unintended Consequences of Closing the Door on Physician Self-Referral. (2016) (3)
PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE? (2005) (3)
Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not. (2017) (3)
LBA-26 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER (2019) (3)
Population-Based Comparison of Patient-Reported Function After 3-Dimensional Conformal Versus Contemporary External Beam Radiation Therapy (2016) (3)
Re: Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4). (2011) (3)
PSA screening and elderly men. (2007) (3)
MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED (2013) (3)
Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. (2016) (3)
Re: Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. (2016) (3)
4: Correlation of International Prostate Symptom Score Bother Question with the Benign Prostatic Hyperplasia Impact Index and SF-12 in a Practice Setting (2005) (3)
Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer (2017) (3)
Re: Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. (2013) (3)
Re: Physicians’ Attitudes about Multiplex Tumor Genomic Testing (2014) (3)
Health-related quality of life results in pathologic Stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy (2008) (3)
MP52-19 IMPACT OF ENZALUTAMIDE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PROSPER STUDY RESULTS (2018) (3)
PROGNOSTIC IMPORTANCE OF POSTIVE APICAL MARGINS IN CLINICALLY LOCALIZED (cT1/cT2) PROSTATE CANCER DURING THE PSA ERA (2008) (3)
Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? (2006) (3)
THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION‐BASED COHORT: PD28‐04 (2017) (3)
755 URINARY FUNCTION EVALUATION IN FEMALE CYSTECTOMY PATIENTS WITH ORTHOTOPIC DIVERSION UTILISING A VALIDATED HEALTH-RELATED QUALITY OF LIFE QUESTIONAIRE (2010) (3)
Quality of life in prostate cancer patients taking androgen deprivation therapy (2006) (3)
The invasive T1 bladder tumor: Contemporary issues and rationale for radical cystectomy (2008) (3)
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region (2021) (3)
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials (2018) (3)
Nationwide Trends inMastectomy for Early-Stage Breast Cancer (2015) (3)
Cancer in a Medicare Population Epidemiology of Vocal Fold Paralyses after Total Thyroidectomy for Well-Differentiated Thyroid (2014) (2)
Characterizing Standardized Letters of Recommendation in Urology Residency Applications. (2021) (2)
Re: Physician practice competition and prices paid by private insurers for office visits. (2015) (2)
Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. (2018) (2)
Functional outcomes after treatment for prostate cancer. (2013) (2)
Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. (2018) (2)
Chapter 28 – Vasculogenic Erectile Dysfunction (2013) (2)
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry. (2018) (2)
Re: Comparative effectiveness of skin antiseptic agents in reducing surgical site infections: a report from the Washington State Surgical Care and Outcomes Assessment Program. (2014) (2)
Pivotal trial of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Two-year follow-up (2020) (2)
Considering quantity and quality of life in metastatic castration-naive prostate cancer. (2018) (2)
The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy (2021) (2)
PWM12: LONGITUDINAL DIFFERENCES IN PSYCHOLOGICAL ADJUSTMENT FOR MEN WITH ERECTILE DYSFUNCTION: RESULTS FROM EXCEED (2003) (2)
Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients (2022) (2)
The Impact of Prostate Cancer Diagnosis and Post-treatment Sexual Dysfunction on Quality of Life (2009) (2)
Creation of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort. (2015) (2)
Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma (2021) (2)
Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer (2007) (2)
Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence. (2017) (2)
Re: Relationship between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. (2015) (2)
Re: Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. (2012) (2)
Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. (2006) (2)
Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). (2016) (2)
Laparoscopic urological oncology: here come the outcomes! (2005) (2)
A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. (2020) (2)
Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry. (2015) (2)
Re: Effect of Electroacupuncture on Urinary Leakage among Women with Stress Urinary Incontinence: A Randomized Clinical Trial. (2018) (2)
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis (2020) (2)
622 ONCOLOGIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH LOCALLY ADVANCED DISEASE (2007) (2)
Cigarette Smoking and Risk of Prostate Cancer in Middle-Aged Men 1 (2003) (2)
342 5 YEAR COST ANALYSIS OF INTRA-DETRUSOR INJECTION OF BOTULINUM TOXIN TYPE A AND AUGMENTATION CYSTOPLASTY FOR REFRACTORY NEUROGENIC DETRUSOR OVERACTIVITY (2010) (2)
Re: Retropubic versus transobturator midurethral slings for stress incontinence. (2012) (2)
Time to raise the bar in localised prostate cancer (2013) (2)
Re: Survey shows that at least some physicians are not always open or honest with patients. (2012) (2)
Re: Impact of Hair Removal on Surgical Site Infection Rates: A Prospective Randomized Noninferiority Trial. (2017) (1)
Quality of life and satisfaction with outcome among prostate-cancer survivors (2008) (1)
Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer (2006) (1)
Re: Association between Cannabis Use and the Risk of Bladder Cancer: Results from the California Men's Health Study. (2015) (1)
THE EFFECT OF NERVE SPARING STATUS ON SEXUAL FUNCTION: 3‐YEAR RESULTS FROM THE CEASAR STUDY: PD18‐10 (2017) (1)
Re: The slowdown in health care spending in 2009-11 reflected factors other than the weak economy and thus may persist. (2013) (1)
Re: Giving office-based physicians electronic access to patients' prior imaging and lab results did not deter ordering of tests. (2012) (1)
Re: Health care coverage under the Affordable Care Act--a progress report. (2015) (1)
Racial variation in follow-through of a positive screening test for prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (2011) (1)
Re: US Physician Practices Spend More than $15.4 Billion Annually to Report Quality Measures. (2016) (1)
Re: The Influence of Body Mass Index on the Cost of Radical Prostatectomy for Prostate Cancer (2011) (1)
Survival associated with treatment vs. observation of localized prostate cancer in elderly men (2007) (1)
American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
Health outcomes in older men with localized prostate cancer: Results from the Prostate Cancer Outcomes Study (2006) (1)
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (1)
A Novel Algorithm Using Claims Data to Identify Patients with Castration-Resistant Prostate Cancer (CRPC) (2013) (1)
Chapter 6 – Health-Related Quality of Life Issues in Urologic Oncology (2005) (1)
Re: Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey. (2012) (1)
Re: A comparison of hospital administrative costs in eight nations: US costs exceed all others by far. (2015) (1)
Re: Use of complementary and alternative medicine among men with prostate cancer in a rural setting. (2012) (1)
Re: the many different prices paid to providers and the flawed theory of cost shifting: is it time for a more rational all-payer system? (2012) (1)
Out-of-pocket costs for commercially insured patients with localized prostate cancer. (2021) (1)
The more, the merrier: including a medical oncologist in treatment planning for localized prostate cancer. (2014) (1)
Phase III PreventionTrial of Fenretinide in Patients with Resected Non ^ Muscle-Invasive Bladder Cancer (2007) (1)
Re: National Trends in Patient Safety for Four Common Conditions, 2005-2011 (2014) (1)
Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. (2016) (1)
Re: Narrow Networks on the Health Insurance Marketplaces: Prevalence, Pricing, and the Cost of Network Breadth. (2018) (1)
Re: physician documentation of fluoroscopy time in voiding cystourethrography reports correlates with lower fluoroscopy times: a surrogate marker of patient radiation exposure. (2012) (1)
Re: Sustained Gains in Coverage, Access, and Affordability under the ACA: A 2017 Update. (2018) (1)
Re: Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. (2012) (1)
PD23-11 VARIATION IN EVALUATION OF HEMATURIA BY GENDER, RACE, AND RISK FACTORS FOR BLADDER CANCER (2015) (1)
ACA, MACRA: What they mean for you, patients (2015) (1)
Re: Surgical site infections following ambulatory surgery procedures. (2014) (1)
Re: US physician practices versus Canadians: spending nearly four times as much money interacting with payers. (2012) (1)
Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study (2022) (1)
Re: variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. (2014) (1)
Re: Supporting Informed Decision Making for Prostate Specific Antigen (PSA) Testing on the Web: An Online Randomized Controlled Trial (2011) (1)
RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS (2009) (1)
MP76-07 UTILIZATION OF AN INTERNET OF THINGS INDOOR GPS SYSTEM AND TIME-DRIVEN ACTIVITY-BASED COSTING TO ENHANCE HEALTH CARE DELIVERY IN A UROLOGIC ONCOLOGY CLINIC: A PROOF-OF -PRINCIPLE (2018) (1)
Re: Changing physician incentives for affordable, quality cancer care: results of an episode payment model. (2015) (1)
Re: Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. (2013) (1)
Re: Uncompensated Care Decreased at Hospitals in Medicaid Expansion States but Not at Hospitals in Nonexpansion States. (2017) (1)
Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. (2017) (1)
Re: the impact of health information technology and e-health on the future demand for physician services. (2014) (1)
Re: hospital pay-for-performance programs in Maryland produced strong results, including reduced hospital-acquired conditions. (2013) (1)
Re: Economic Burden of Chronic Conditions among Survivors of Cancer in the United States (2017) (1)
Re: health benefits in 2012: moderate premium increases for employer-sponsored plans; young adults gained coverage under ACA. (2013) (1)
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials (2018) (1)
Re: Relationship between occurrence of surgical complications and hospital finances. (2013) (1)
Accountable care organizations in surgery: location, location, location: Comment on "will accountable care organizations cut costs and improve quality for inpatient surgery?". (2013) (1)
Re: safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. (2013) (1)
MP22-02 COMPARISON OF PATIENT-REPORTED OUTCOMES AFTER EXTERNAL BEAM RADIATION THERAPY AND COMBINED EXTERNAL BEAM WITH LOW-DOSE RATE BRACHYTHERAPY BOOST IN MEN WITH LOCALIZED PROSTATE CANCER (2018) (1)
Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS). (2013) (1)
58 AGE, COMORBIDITY, AND RISK OF OTHER-CAUSE MORTALITY: FOURTEEN-YEAR RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY (PCOS) (2013) (1)
672: Five-Year Urinary and Sexual Outcomes after Watchful Waiting: Results from the Prostate Cancer Outcomes Study (2005) (1)
PREDICTORS OF RECURRENCE IN PATIENTS WITH LOW VOLUME LYMPH NODE DISEASE FOLLOWING RADICAL CYSTECTOMY (2008) (1)
Benchmarking patient satisfaction scores in a colorectal patient population (2020) (1)
Re: Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. (2016) (1)
Pivotal study of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Preliminary results (2019) (1)
Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. (2015) (1)
Re: Fee-for-Service, while Much Maligned, Remains the Dominant Payment Method for Physician Visits. (2016) (1)
SURGEON ENGAGEMENT IN EARLY ACCOUNTABLE CARE ORGANIZATIONS: PD32‐04 (2017) (1)
Physician Performance Measurement Set (2008) (1)
Re: Early prostate cancer-which treatment do men prefer and why? (2012) (1)
Re: higher fees paid to us physicians drive higher spending for physician services compared to other countries. (2012) (1)
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function (2021) (1)
Quality-of-life instruments for prostate cancer (2008) (1)
Re: Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. (2013) (1)
Re: Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. (2016) (1)
Re: Demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces long-term regret: a comparative cohort study. (2012) (1)
Re: Financial Hardship Associated with Cancer in the United States: Findings from a Population-Based Sample of Adult Cancer Survivors. (2016) (1)
69 COMPLIANCE WITH RECOMMENDATIONS IN THE METABOLIC EVALUATION OF NEPHROLITHIASIS: A SURVEY OF THE AMERICAN UROLOGICAL ASSOCIATION (2011) (1)
Urology Board Review (2010) (1)
Standardized Letters of Recommendation and Success in the Urology Match. (2022) (1)
Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. (2017) (1)
Re: Association of the 2011 ACGME resident duty hour reform with general surgery patient outcomes and with resident examination performance. (2015) (1)
Re: States with the least restrictive regulations experienced the largest increase in patients seen by nurse practitioners. (2014) (1)
Editorial comment. (2012) (1)
Re: Physicians with the Least Experience have Higher Cost Profiles than do Physicians with the Most Experience (2013) (1)
Re: Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. (2016) (1)
Treatment for postprostatectomy incontinence: is this as good as it gets? (2011) (1)
527 CHANGING UTILIZATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPIES FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER PUBLICATION OF LANDMARK MANUSCRIPTS (2012) (1)
Editorial comment. (2011) (1)
Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. (2012) (1)
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide. (2021) (1)
Re: Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. (2012) (1)
Re: large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. (2012) (1)
Phase III bladder cancer chemoprevention trial with fenretinide. (2006) (1)
Su1137 Dilate or Medicate? a Decision Analysis of Initial Treatment Strategies in Eosinophilic Esophagitis (2012) (1)
Learning to see the forest through the trees. (2014) (1)
Re: First national survey of ACOs finds that physicians are playing strong leadership and ownership roles. (2015) (1)
Re: Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era (2014) (1)
The hidden agenda in the release of the Medicare physician reimbursement data. (2014) (1)
Predicting the Probability of 90-day Survival in Elderly Bladder Cancer Patients Treated with Radical Cystectomy (2019) (1)
Insulin-LikeGrowth Factor-I, Insulin-LikeGrowth FactorBinding Protein-3 andRiskof Benign Prostate Hyperplasia in the ProstateCancer PreventionTrial (2008) (1)
MP27-11 DISTINCT SIDE EFFECT PROFILES AFTER CONTEMPORARY TREATMENT OF LOCALIZED PROSTATE CANCER (2015) (1)
RACIAL DISPARITY AND ADHERENCE TO QUALITY MEASURES FOR RADIATION THERAPY OF PROSTATE CANCER: MP92‐08 (2017) (1)
Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED. (2014) (1)
Survivorship and quality of life in prostate cancer (2015) (1)
How to Engage Specialists in Accountable Care Organizations (2018) (1)
PATIENT‐IDENTIFIED FACTORS AFFECTING TREATMENT DECISIONS FOR ADVANCED PROSTATE CANCER: MP57‐07 (2017) (1)
Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention. (2016) (1)
Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry. (2016) (1)
Re: Course and Predictors of Cognitive Function in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. (2016) (1)
Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma (2006) (1)
Prostate-Specific Antigen Screening for Prostate Cancer: Yes, No, or Maybe? (2020) (1)
Re: Americans Support Price Shopping for Health Care, but Few Actually Seek out Price Information. (2018) (1)
Re: Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. (2012) (1)
785 URINARY DIVERSION IN WOMEN FOLLOWING RADICAL CYSTECTOMY: A SINGLE CENTER COMPARISON AND UPDATE ON OUTCOMES (2007) (1)
Patient expectations from systemic treatment of metastatic prostate cancer (mPC). (2017) (1)
Re: how well informed are women who undergo urodynamic testing? (2012) (1)
Re: Preliminary Treatment Considerations Among Men With Newly Diagnosed Prostate Cancer (2011) (0)
Re: Acquisition of MRI Equipment by Doctors Drives up Imaging Use and Spending (2011) (0)
Editorial Comment. (2018) (0)
The Polit ics of Prostate Cancer Screening (0)
Re: variation among primary care physicians in prostate-specific antigen screening of older men. (2014) (0)
MP53-06 RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: EFFECT OF TIMING OF POST-PROSTATECTOMY RADIATION ON FUNCTIONAL OUTCOMES (2020) (0)
MP44-07 DEVELOPMENT AND VALIDATION OF A WEB-BASED TOOL TO PREDICT SEXUAL, URINARY, AND BOWEL FUNCTION LONGITUDINALLY AFTER RADIATION THERAPY, SURGERY, OR OBSERVATION (2019) (0)
CARDIOVASCULAR RISK FACTORS AND DISEASE IN WOMEN WITH OVERACTIVE BLADDER VS STRESS INCONTINENCE CONTROLS (2010) (0)
Do accountable care organizations affect race mediated differences in cancer screening (2018) (0)
Re: Overweight Men with Nonobstructive Azoospermia Have Worse Pregnancy Outcomes after Microdissection Testicular Sperm Extraction (2013) (0)
Re: Massachusetts health reforms: uninsurance remains low, self-reported health status improves as state prepares to tackle costs. (2012) (0)
Re: Costs of Ambulatory Care Related to Female Pelvic Floor Disorders in the United States (2011) (0)
Re: An Early Look at Changes in Employer-Sponsored Insurance under the Affordable Care Act. (2015) (0)
Ethical Issues in Clinical Research (2006) (0)
MP31-15 IMPACT OF HEALTH LITERACY ON DISCHARGE DISPOSITION FOLLOWING RADICAL CYSTECTOMY (2016) (0)
Re: Association of Hospital Participation in a Quality Reporting Program with Surgical Outcomes and Expenditures for Medicare Beneficiaries. (2015) (0)
Trends in Care Delivery for Disorders of the Female Pelvic Floor (2012) (0)
Re: Physicians Versus Hospitals as Leaders of Accountable Care Organizations (2011) (0)
PCN145 A COMPARISON OF PHYSICIAN AND PATIENT DECISION MAKING FOR FIRST VERSUS SECOND OPINIONS AMONG MEN WITH LOCAL STAGE PROSTATE CANCER (2010) (0)
LONG-TERM OUTCOME OF PATIENTS WITH GLEASON ≤6 TREATED BY RADICAL PROSTATECTOMY (2008) (0)
Table 2, IOM 2009 recommendations for weight gain during pregnancy by prepregnancy BMI (2010) (0)
Title Prostate Cancer Registries : Current Status and Future Directions Permalink (2016) (0)
Oncology: Prostate/Testis/Penis/Urethra Interpretation of Domain Scores on the EPICdHow Does the Domain Score Translate into Functional Outcomes? (0)
Comparing the Effects of Surgery, Radiation Therapy, and Active Surveillance on Men with Localized Prostate Cancer -- The CEASAR Study (2020) (0)
Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer (2018) (0)
Re: Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. (2012) (0)
Re: Outcomes of Daytime Procedures Performed by Attending Surgeons after Night Work. (2016) (0)
67: Medication Treatment Patterns in a Benign Prostatic Hyperplasia California Medicaid Population (2007) (0)
MP82-13 IMPACT OF VARIANT HISTOLOGY ON SURVIVAL AND RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
Re: National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. (2013) (0)
Re: Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians. (2012) (0)
Re: High Volume is the Key for Improving In-Hospital Outcomes after Radical Prostatectomy: A Total Population Analysis in Germany from 2006 to 2013. (2017) (0)
Erectile function outcome reporting after clinically localized prostate cancer treatment (2007) (0)
Figure 1, Annotated analytic framework indicating identified gaps in methods and content (2010) (0)
General Q uality o f L ife 2 Y ears F ollowing T reatment f or Prostate C ancer: W hat I nfluences O utcomes? R esults F rom t he Prostate C ancer O utcomes S tudy (2003) (0)
Re: e-prescribing adoption and use increased substantially following the start of a federal incentive program. (2014) (0)
Re: today's 'meaningful use' standard for medication orders by hospitals may save few lives; later stages may do more. (2012) (0)
Re: delivering affordable cancer care in high-income countries. (2012) (0)
MP09-01 RACIAL VARIATION IN PATIENT-REPORTED OUTCOMES FOLLOWING TREATMENT FOR LOCALIZED PROSTATE CANCER: RESULTS FROM THE CEASAR STUDY (2016) (0)
Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer (2017) (0)
136 INFLUDENCE OF RACE AND COMORBIDITY ON THERAPY FOR PROSTATE CANCER: EVOLUTION OVER 15 YEARS (2013) (0)
Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. (2006) (0)
INSURANCE STATUS AFFECTS QUALITY OF LIFE OUTCOMES IN MEN WITH PROSTATE CANCER: RESULTS FROM THE CAPSURE [TM] DATABASE (1999) (0)
Re: A Comparison of Web-Based versus Print-Based Decision Aids for Prostate Cancer Screening: Participants' Evaluation and Utilization. (2017) (0)
Re: Changes in Hospital Quality Associated with Hospital Value-Based Purchasing. (2017) (0)
Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort. (2017) (0)
Diffusion of brachytherapy for localized prostate cancer across SEER sites from 1992 to 2001 (2005) (0)
MP51-15 DO ACCOUNTABLE CARE ORGANIZATIONS EXACERBATE RACE MEDIATED DIFFERENCES IN CANCER SCREENING? (2018) (0)
Re: Urologist Participation in Medicare Shared Savings Program Accountable Care Organizations (ACOs). (2017) (0)
Re: Effect of insurance expansion on utilization of inpatient surgery. (2015) (0)
Editorial Comment. (2016) (0)
Editorial Comment. (2019) (0)
Re: Postgame analysis: using video-based coaching for continuous professional development. (2012) (0)
PD08-07 ASSOCIATION BETWEEN PELVIC NODAL RADIOTHERAPY AND PATIENT-REPORTED OUTCOMES AMONG MEN UNDERGOING EXTERNAL-BEAM RADIOTHERAPY FOR PROSTATE CANCER (2021) (0)
PD52-08 PRE-OPERATIVE NARCOTIC USE IS ASSOCIATED WITH INCREASING LENGTH OF STAY AND POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
Re: the new era of payment reform, spending targets, and cost containment in massachusetts: early lessons for the nation. (2013) (0)
439 THE ASSOCIATION BETWEEN DIFFUSION OF THE SURGICAL ROBOT AND RADICAL PROSTATECTOMY RATES (2011) (0)
1239: Urinary Diversion in Women Following Radical Cystectomy: A Single Center Comparison and Update on Outcomes (2006) (0)
Reply by Authors. (2020) (0)
Redefining Prostate Cancer: An Innovative Guide to Diagnosis and Treatment, S. Lamm, H. Lepor, D. Sperling. Spry Publishing, Ann Arbor, Michigan (2013), 176 pages (2014) (0)
Re: Projecting the Urology Workforce over the Next 20 Years. (2017) (0)
PD17-02 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: TWO-YEAR FOLLOW-UP (2020) (0)
Re: Survey Finds Few Orthopedic Surgeons Know the Costs of the Devices they Implant (2014) (0)
Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. (2017) (0)
Re: Robot-Assisted Surgery for Kidney Cancer Increased Access to a Procedure that can Reduce Mortality and Renal Failure. (2015) (0)
Sa1281 Developmental Characteristics of Extraesophageal Reflux-Related Patient-Reported Outcome Measures: A Systematic Review (2016) (0)
Re: for states that opt out of Medicaid expansion: 3.6 million fewer insured and $8.4 Billion less in federal payments. (2014) (0)
448 LONG TERM TREATMENT REGRET AMONG MEN TREATED WITH RADICAL PROSTATECTOMY OR EXTERNAL BEAM RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY (2013) (0)
Re: Coverage of newborn and adult male circumcision varies among public and private US payers despite health benefits. (2012) (0)
Association between body mass index and localized prostate cancer management and disease‐specific quality of life (2022) (0)
Re: National Health Spending in 2012: Rate of Health Spending Growth Remained Low for the Fourth Consecutive Year (2014) (0)
Five-Year Outcomes From a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy With Low Dose-Rate Brachytherapy Boost and Prostatectomy for Localized Prostate Cancer. (2021) (0)
Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men. (2017) (0)
Re: What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial. (2012) (0)
Editorial comment. (2010) (0)
Re: medical communication companies and industry grants. (2014) (0)
MP87-06 SARCOPENIA RATHER THAN OBESITY MAY BE ASSOCIATED WITH SURVIVAL AMONG PATIENTS WITH METASTATIC OR CASTRATE RESISTANT PROSTATE CANCER (2018) (0)
Sensitivity of Medicare claims to identify recurrence. (2013) (0)
Re: Long-term effect of hospital pay for performance on mortality in England. (2015) (0)
Re: use of statins and the risk of death in patients with prostate cancer. (2014) (0)
Re: Can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. (2011) (0)
73 RACIAL VARIATION IN THE UTILIZATION OF HIGH-VOLUME SURGEONS AND HOSPITALS FOR RADICAL PROSTATECTOMY (2011) (0)
Socioeconomic factors, urological epidemiology and practice patterns. (2008) (0)
Re: Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. (2013) (0)
Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. (2018) (0)
Editorial comment. (2010) (0)
PCN89 RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS (2008) (0)
Re: Efficiency, Satisfaction, and Costs for Remote Video Visits following Radical Prostatectomy: A Randomized Controlled Trial. (2016) (0)
Seminar article Quality of life in patients with localized prostate cancer (2005) (0)
Re: Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. (2016) (0)
Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder. (2018) (0)
Re: Better Patient Care at High-Quality Hospitals May Save Medicare Money and Bolster Episode-Based Payment Models. (2017) (0)
MP73-05 PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 4-YEAR FOLLOW UP (2023) (0)
PD6-05 CHANGE IN PREDICTED PROGNOSIS AFTER RADICAL PROSTATECTOMY DURING FOLLOW-UP IN AN ACTIVE SURVEILLANCE COHORT (2015) (0)
Re: Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. (2014) (0)
Urology Board Review, 3rd ed., S.W. Leslie. McGraw Hill Medical, New York (2009), 521 pages (2010) (0)
Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. (2017) (0)
DISPARITY IN MINORITY REPRESENTATION WITHIN MEDICARE ACCOUNTABLE CARE ORGANIZATIONS: PD06‐08 (2017) (0)
The Impact of Gender on Use of Pelvic Lymphadenectomy at the Time of Radical Cystectomy (2014) (0)
Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis (2020) (0)
Re: Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. (2012) (0)
Re: urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in medicare population. (2012) (0)
Re: Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated with New Cancer Medicines. (2017) (0)
PD25-03 ASSOCIATION BETWEEN FINANCIAL BURDEN AND TREATMENT REGRET IN MEN WITH LOCALIZED PROSTATE CANCER (2022) (0)
Four-year follow-up of MRI-guided Transurethral Ultrasound Ablation (TULSA) in men with localized prostate cancer (2023) (0)
Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial (2017) (0)
Re: Vertical integration: hospital ownership of physician practices is associated with higher prices and spending. (2015) (0)
Re: long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. (2013) (0)
Re: Emergency Department Revisits for Patients with Kidney Stones in California. (2016) (0)
79 WOMEN ARE LESS LIKELY TO RECEIVE EVIDENCE-BASED PROCESSES OF CARE FOR SURGICAL TREATMENT OF BLADDER CANCER COMPARED TO MEN (2013) (0)
652: Ten Year Outcomes Following Treatment for Clinically Localized Prostate Cancer: A Population Based Study (2006) (0)
418 NATIONAL TRENDS IN UTILIZATION OF RADICAL PROSTATECTOMY FROM 2000-2008 (2012) (0)
Re: Kentucky's Medicaid Expansion Showing Early Promise on Coverage and Access to Care. (2016) (0)
HEALTH SYSTEM STRUCTURE AND READMISSIONS AFTER UROLOGIC CANCER SURGERY: PD14‐07 (2017) (0)
THE ASSOCIATION OF BMI AND DM WITH SURVIVAL AMONG PATIENTS WITH METASTATIC OR CASTRATION‐RESISTANT PROSTATE CANCER.: MP57‐14 (2017) (0)
Re: Preoperative Frailty Predicts Postoperative Complications and Mortality in Urology Patients. (2017) (0)
Patient-Reported Outcomes through Five Years following External Beam Radiotherapy or External Beam Radiotherapy with Low-Dose-Rate Brachytherapy Boost for Localized Prostate Cancer (2020) (0)
Re: Types and Distribution of Payments from Industry to Physicians in 2015. (2017) (0)
Clinical trials in urology (2010) (0)
Re: The Affordable Care Act reduces emergency department use by young adults: evidence from three states. (2015) (0)
Re: Association of Pioneer Accountable Care Organizations vs Traditional Medicare Fee for Service with Spending, Utilization, and Patient Experience. (2016) (0)
190 Outpatient Versus Inpatient Observation After Percutaneous Native Kidney Biopsy; A Cost-Minimization Study (2011) (0)
Re: Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. (2013) (0)
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP). (2019) (0)
‘Killing two birds with one stone’: patient‐reported quality‐of‐life outcomes from the Prostate Testing for Cancer and Treatment (ProtecT) trial (2016) (0)
Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study. (2018) (0)
Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. (2021) (0)
Re: Trends in Surgical Management and Pre-Operative Urodynamics in Female Medicare Beneficiaries with Mixed Incontinence. (2016) (0)
Re: At Federally Funded Health Centers, Medicaid Expansion was Associated with Improved Quality of Care. (2017) (0)
Re: Health care cost containment strategies used in four other high-income countries hold lessons for the United States. (2013) (0)
Knowledge of Low-risk Prostate Cancer Treatment Options Survey (2020) (0)
Quality of Life Measures (2015) (0)
The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer. (2017) (0)
Surgeons’ Perspective of Decision Making in Recurrent Diverticulitis (2022) (0)
Adult UrologyUrological SurveySocioeconomic Factors, Urological Epidemiology and Practice Patterns (2008) (0)
253: Prosate Cancer and the will Rogers Phenomenon (2005) (0)
Re: Identifying Drivers of Episode Cost Variation with Radical Prostatectomy. (2017) (0)
MP25-11 PHYSICIAN-LEVEL VARIATION IN THE USE OF OBSERVATION FOR LOCALIZED PROSTATE CANCER (2016) (0)
Reply to I.E. Haines. (2017) (0)
Racial variation in receipt of quality radiation therapy for prostate cancer (2018) (0)
270 INAPPROPRIATE USE OF IMAGING TO STAGE INCIDENT PROSTATE CANCER IN THE MEDICARE POPULATION (2010) (0)
Re: Disparities in Stage at Diagnosis, Treatment, and Survival in Nonelderly Adult Patients with Cancer According to Insurance Status. (2015) (0)
PD41-04 ORAL NUTRITION INTERVENTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL (2018) (0)
Re: effect of nonpayment for preventable infections in U.S. Hospitals. (2013) (0)
The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers. (2016) (0)
Association between surgical volume and survival among patients with variant histologies of bladder cancer. (2021) (0)
Re: Liking Health Reform but Turned Off by Toxic Politics. (2017) (0)
FIRST-YEAR COSTS OF TREATING PROSTATE CANCER DIAGNOSED AT DIFFERENT STAGES: RESULTS FROM THE CaPSURE [trade mark sign] DATABASE (1999) (0)
Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT). (2014) (0)
PD18-03 THE IMPACT OF HOSPITAL VOLUME ON SHORT-TERM AND LONG-TERM OUTCOMES FOR PATIENTS UNDERGOING RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
Re: What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy? (2012) (0)
Re: Explaining racial differences in prostate cancer mortality. (2013) (0)
441 RACIAL VARIATION IN THE QUALITY OF CARE AMONG PATIENTS UNDERGOING CYSTECTOMY FOR BLADDER CANCER (2011) (0)
Re: Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. (2012) (0)
Comparative effectiveness research from the perspective of a surgeon-scientist. (2012) (0)
Re: The Practice of Imaging Self-Referral Doesn't Produce Much One-Stop Service (2011) (0)
Re: views of US physicians about controlling health care costs. (2014) (0)
[Table, List of Ongoing Studies]. (2010) (0)
Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer (2023) (0)
Conclusions: Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function. These changes influenced satisfaction with treatment outcomes among patients and their spouses or partners. (2008) (0)
Re: factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. (2013) (0)
Re: Association between hospital conversions to for-profit status and clinical and economic outcomes. (2015) (0)
Re: Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries. (2016) (0)
Re: Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. (2015) (0)
Re: Lessons from a patient experience survey in a randomized surgical trial of treatment of stress urinary incontinence in women. (2012) (0)
966 ONCOLOGIC OUTCOMES FOLLOWING ROBOTIC-ASSISTED LAPAROSCOPIC VS. OPEN RADICAL PROSTATECTOMY FOR INTERMEDIATE AND HIGH-RISK PROSTATE CANCER (2013) (0)
Sa1295 Developmental Characteristics of GERD and Dysphagia-Related Patient-Reported Outcome Measures: A Systematic Review (2016) (0)
Re: Effect of age, tumor risk, and comorbidity on competing risks for survival in a u.s. Population-based cohort of men with prostate cancer. (2013) (0)
Re: Attention to surgeons and surgical care is largely missing from early medicare accountable care organizations. (2015) (0)
PD30-07 PATIENT REPORTED FUNCTIONAL OUTCOMES AFTER 5 YEARS IN MEN WITH LOW- AND FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER (2019) (0)
MEDICARE ACO ENROLLMENT AND THE PREVALENCE OF PROSTATE CANCER SCREENING: MP32‐05 (2017) (0)
Re: Insights from Transformations Under Way at Four Brookings-Dartmouth Accountable Care Organization Pilot Sites (2013) (0)
Editorial comment. (2013) (0)
Highlights of USPSTF Updates to Prostate Cancer Screening Guidelines (2018) (0)
Sample Abstract and Full-Text Review Forms (2012) (0)
Re: Ultrasonography versus computed tomography for suspected nephrolithiasis. (2015) (0)
5: Do Socioeconomic Characteristics Play a Role in Treatment Choice for BPH? (2006) (0)
MP48-18 PATIENT SATISFACTION WITH THE PHYSICIAN RELATIONSHIP IMPACTS THE EFFECTIVENESS OF DECISION AIDS IN MEN WITH PROSTATE CANCER (2023) (0)
Clinical Pragmatism Should Prevail Over Biological Orthodoxy: "Pro" Perspective. (2023) (0)
Re: Variation and Predictors of Surgical Case Costs among Urologists. (2017) (0)
Re: Gaining Coverage in 2014: New Estimates of Marketplace and Medicaid Transitions. (2017) (0)
Re: Profiling Individual Surgeon Performance Using Information from a High-Quality Clinical Registry: Opportunities and Limitations. (2016) (0)
Re: a simulation shows limited savings from meeting quality targets under the medicare shared savings program. (2013) (0)
Re: Concentration in Orthopedic Markets was Associated with a 7 Percent Increase in Physician Fees for Total Knee Replacements. (2015) (0)
316 COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF APICAL PROLAPSE REPAIR WITH EITHER SACROCOLPOPEXY OR SACROSPINOUS FIXATION (2011) (0)
Re: Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results from the Health Professionals Follow-up Study. (2015) (0)
Issue information (2013) (0)
PD27-07 PROSTATE VOLUME, BASELINE URINARY SYMPTOMS, AND THEIR ASSOCIATION WITH POST-TREATMENT URINARY FUNCTION IN MEN TREATED FOR LOCALIZED PROSTATE CANCER (2022) (0)
Re: Changes in Health Status and Care Use after ACA Expansions among the Insured and Uninsured. (2017) (0)
MP44-16 INTERPRETATION OF DOMAIN SCORES ON THE EXPANDED PROSTATE CANCER INDEX COMPOSITE: HOW DOES THE DOMAIN SCORE TRANSLATE INTO FUNCTIONAL OUTCOME? (2019) (0)
MP58-08 DO LOW RISK MEN IN AN ACTIVE SURVEILLANCE COHORT REQUIRE ANNUAL BIOPSIES? (2014) (0)
Re: Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality after Radical Cystectomy. (2017) (0)
Re: Procedures take less time at ambulatory surgery centers, keeping costs down and ability to meet demand up. (2015) (0)
Re: Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. (2017) (0)
LONG-TERM OUTCOMES OF RADICAL PROSTATECTOMY (2010) (0)
Re: Introduction of Surgical Safety Checklists in Ontario, Canada (2014) (0)
Re: Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013. (2016) (0)
Re: Trends in Health Insurance Enrollment, 2013-15. (2016) (0)
A discussion on the AUA castrateresistant prostate cancer guidelines. (2017) (0)
Editorial Comment. (2015) (0)
Secondary Therapy In Localized Prostate Cancer: Results From The Prostate Cancer Outcomes Study (2008) (0)
PCN136 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS (2009) (0)
MP29-05 TREATMENT PATTERN AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN THE UNITED STATES (US) (2023) (0)
PD34-11 TEMPORAL TRENDS IN THE UTILIZATION OF OBSERVATION FOR CLINICALLY LOCALIZED PROSTATE CANCER (2014) (0)
MP6-16 GENDER, RACE, AND VARIATION IN THE WORKUP OF HEMATURIA (2014) (0)
449 THE BURDEN OF PRE-TREATMENT URINARY, SEXUAL, AND BOWEL DYSFUNCTION ACROSS TWO DECADES OF PROSTATE CANCER: RESULTS FROM PCOS AND CEASAR (2013) (0)
Obesity, body composition, and prostate cancer (2012) (0)
Figure 3, Disposition of articles for updating status of maternal weight gain literature (2010) (0)
Active Surveillance for Prostate Cancer under the Patient Protection and Affordable Care Act (2015) (0)
Re: Nurse-led flexible cystoscopy in Australia: initial experience and early results. (2013) (0)
PD55-06 COMPARISON OF MRI/FUSION VERSUS TRUS CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS (2019) (0)
Re: Massachusetts General Physicians Organization's quality incentive program produces encouraging results. (2014) (0)
1413 PREDICTING THE PROBABILITY OF 90-DAY SURVIVAL IN ELDERLY BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2011) (0)
MP27-19 COMPARATIVE OUT-OF-POCKET COSTS OF TREATMENT OPTIONS IN PRIVATELY INSURED PATIENTS WITH ADVANCED PROSTATE CANCER (2022) (0)
Prostate cancer: Quality of life after radiation and androgen deprivation (2009) (0)
1900 WORTH A SECOND LOOK: RATES OF UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY AFTER RESTAGING TURBT FOR PERSISTENT T1 UROTHELIAL CARCINOMA (2012) (0)
What is “biochemical failure” in prostate cancer? (2002) (0)
Magnetic Resonance Imaging for Locating Nonpalpable Undescended Testicles: A Meta-analysis abstract (2013) (0)
Treatment decision making in metastatic prostate cancer (mPC). (2020) (0)
Re: Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer (2014) (0)
Editorial Comment. (2021) (0)
Re: Knowledge and Use of Finasteride for the Prevention of Prostate Cancer (2011) (0)
MP48-09 LEVERAGING IMPLEMENTATION SCIENCE TO SUCCESSFULLY SCALE A SHARED DECISION MAKING PROGRAM FOR MEN WITH PROSTATE CANCER (2023) (0)
Re: The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions. (2017) (0)
Re: How Medicare Could Use Comparative Effectiveness Research in Deciding on New Coverage and Reimbursement (2011) (0)
Re: Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. (2012) (0)
Re: Electronic Health Record Logs Indicate that Physicians Split Time Evenly between Seeing Patients and Desktop Medicine. (2018) (0)
MP11-07 SELF-REFERRAL FOR ADVANCED IMAGING IN THE MANAGEMENT OF URINARY STONE DISEASE: IMPLICATIONS FOR UTILIZATION AND QUALITY OF CARE (2014) (0)
Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. (2016) (0)
Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder. (2011) (0)
Assessing Quality of Life (2000) (0)
PD12-03 IMPACT OF ADHERENCE TO QUALITY MEASURES FOR LOCALIZED PROSTATE CANCER ON HEALTH-RELATED QUALITY OF LIFE OUTCOMES (2015) (0)
Re: Readmissions in the postoperative period following urinary diversion. (2011) (0)
Reply from the Authors (1996) (0)
THREE‐YEAR FUNCTIONAL OUTCOMES AFTER RADIATION, SURGERY OR OBSERVATION FOR LOCALIZED PROSTATE CANCER IN THE CEASAR STUDY: PD09‐03 (2017) (0)
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. (2018) (0)
TWO-STAGE INFLATABLE PENILE PROSTHESIS PLACEMENT FOLLOWING RADICAL CYSTECTOMY IS A SAFE AND EFFECTIVE WAY TO TREAT ERECTILE DYSFUNCTION RELATED TO CANCER SURGERY (2008) (0)
PWM13: PREDICTORS OF RESPONSE TO ERECTILE DYSFUNCTION TREATMENT AT 12 MONTHS: RESULTS FROM THE EXCEED DATABASE (2003) (0)
The Association Between Financial Toxicity and Treatment Regret in Men With Localized Prostate Cancer (2022) (0)
Patient-reported outcome measures in men with non-metastatic castration-resistant prostate cancer: Baseline data from the PROSPER trial (2018) (0)
Re: public financing of the Medicare program will make its uniform structure increasingly costly to sustain. (2014) (0)
Re: Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer (2011) (0)
MP-09.19: Why men on watchful waiting for LUTS/BPH start medical therapy: findings from the USA BPH Registry & Patient Survey (2006) (0)
Re: Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. (2012) (0)
Re: Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. (2013) (0)
Epidemiological Studies Reporting Prevalence of ED (2004) (0)
Prostate-Specific Antigen Screening for Prostate Cancer : Yes , No , or Maybe ? Moderated by (0)
Re: Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. (2013) (0)
Re: Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. (2011) (0)
Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. (2022) (0)
Re: Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. (2013) (0)
Re: New American Cancer Society process for creating trustworthy cancer screening guidelines. (2012) (0)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (0)
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. (2023) (0)
436: Validation of Rising Prostate Specific Antigen as a Predictor of Prostate Cancer Death Following Treatment of Localized Prostate Cancer with Either Surgery or Radiation (2004) (0)
Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC). (2015) (0)
1226 PERIOPERATIVE COST COMPARISON OF ROBOTIC AND OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER (2012) (0)
Re: fee-for-service will remain a feature of major payment reforms, requiring more changes in medicare physician payment. (2013) (0)
Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality. (2004) (0)
Re: cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. (2013) (0)
MP44-02 POST-OPERATIVE NARCOTIC PRESCRIBING PATTERNS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. (2018) (0)
132 BENCH-MARKING THE USE OF A RAPID RESPONSE TEAM BY SURGICAL SERVICES AT A TERTIARY CARE HOSPITAL (2013) (0)
On the importance of race, socioeconomic status, and comorbidity when evaluating quality of life in men with prostate cancer (2007) (0)
Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic. (2013) (0)
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
Re: Less Physician Practice Competition is Associated with Higher Prices Paid for Common Procedures. (2016) (0)
MP59-10 COST-EFFECTIVE MANAGEMENT OF PELVIC FRACTURE URETHRAL INJURIES USING DECISION TREE ANALYSIS (2016) (0)
Re: Strategies for Identifying and Closing the Gender Salary Gap in Surgery. (2018) (0)
MP53-04 RECOVERY OF SEXUAL FUNCTION IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER (2020) (0)
816: Predictors of long-term Biochemical-Free Survival following Salvage Radical Prostatectomy (2005) (0)
Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery. (2013) (0)
Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events. (2018) (0)
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP) (2018) (0)
Re: Medicare's public reporting initiative on hospital quality had modest or no impact on mortality from three key conditions. (2012) (0)
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer (2022) (0)
MEDICARE ACO ENROLLMENT AND APPROPRIATENESS OF PROSTATE CANCER SCREENING: MP32‐04 (2017) (0)
Prostate Cancer: Localized: Active Surveillance IPD28-04 THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION-BASED COHORT (2017) (0)
Re: the anatomy of health care in the United States. (2014) (0)
THE EFFECT OF PROSTATE CANCER TREATMENT ON PATIENT REPORTED URINARY AND SEXUAL FUNCTION VARIES BY DISEASE SEVERITY: 3‐YEAR RESULTS FROM THE CEASAR STUDY: PD47‐01 (2017) (0)
Re: Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective. (2011) (0)
Re: Decision aids: when 'nudging' patients to make a particular choice is more ethical than balanced, nondirective content. (2013) (0)
Re: Validating the patient safety indicators in the Veterans Health Administration: are they ready for prime time? (2011) (0)
Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. (2011) (0)
Re: Trends in Prostate-Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012. (2016) (0)
UC San Francisco UC San Francisco Previously Published Works Title Contemporary prevalence of pretreatment urinary , sexual , hormonal , and bowel dysfunction : Defining the population at risk for harms of prostate cancer treatment (2014) (0)
Re: Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder (2011) (0)
443 REGIONAL VARIATION IN THE COST OF RADICAL CYSTECTOMY: EVIDENCE FROM THE HEALTHCARE COST AND UTILIZATION PROJECT NATIONWIDE INPATIENT SAMPLE (2011) (0)
Re: The Correlation of Media Ranking's "Best" Hospitals and Surgical Outcomes following Radical Cystectomy for Urothelial Cancer. (2016) (0)
57 ASSOCIATION BETWEEN RACE AND PARTICIPATORY DECISION MAKING (PDM) IN TREATMENT DECISIONS FOR PROSTATE CANCER (PC) MANAGEMENT (2013) (0)
1030 ASSESSMENT OF THE 2002 AJCC NODAL STAGING OF BLADDER UROTHELIAL CARCINOMA (2010) (0)
Re: surgery versus physiotherapy for stress urinary incontinence. (2014) (0)
PD12-06 INCREASED PAYMENT FOR OFFICE-BASED MANAGEMENT OF BLADDER CANCER: UNINTENDED CONSEQUENCES IN A FEE-FOR-SERVICE ENVIRONMENT (2015) (0)
Impact of PSMA-targeted PET/CT in the clinical management of men with advanced prostate cancer. (2022) (0)
Re: Effect of Home Monitoring via Mobile App on the Number of In-Person Visits following Ambulatory Surgery: A Randomized Clinical Trial. (2017) (0)
Re : Mortality after Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer (0)
630 FACTORS ASSOCIATED WITH SATISFACTION WITH PROSTATE CANCER CARE: RESULTS FROM CAPSURE (2011) (0)
MP54-06 EFFECT OF SMOKING ON PROSTATE CANCER SURVIVORS' FUNCTION AND QUALITY OF LIFE: AN ANALYSIS OF THE CEASAR (COMPARATIVE EFFECTIVENESS ANALYSIS OF SURGERY AND RADIATION) STUDY (2023) (0)
PII-LBA5 EVIDENCE OF SUPERIOR QUALITY OF LIFE AFTER ROBOTIC PROSTATECTOMY: RESULTS FROM A POPULATION-BASED ANALYSIS (2015) (0)
Re: Intensity-Modulated Radiotherapy for the Treatment of Prostate Cancer: A Systematic Review and Economic Evaluation (2011) (0)
Re: Medicare's Acute Care Episode Demonstration: Effects of Bundled Payments on Costs and Quality of Surgical Care. (2018) (0)
Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry. (2017) (0)
Re: National Health Spending: Faster Growth in 2015 as Coverage Expands and Utilization Increases. (2017) (0)
Re: despite overall improvement in surgical outcomes since 2000, income-related disparities persist. (2014) (0)
Reply by Authors. (2022) (0)
1510: Gender Differences in the Pathologic Characteristics and Disease Specific Outcomes in Patients with Transitional Cell Carcinoma (TCC) Following Radical Cystectomy (2007) (0)
Re: Quality of Life in Children With Vesicoureteral Reflux as Perceived by Children and Parents (2012) (0)
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (2020) (0)
Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry. (2016) (0)
Re: Program Directors' Criteria for Selection into Urology Residency. (2016) (0)
419 FACTORS ASSOCIATED WITH THE EARLY ACQUISITION OF THE SURGICAL ROBOT BY HOSPITALS IN THE UNITED STATES (2012) (0)
Re: Marketplace Plans with Narrow Physician Networks Feature Lower Monthly Premiums than Plans with Larger Networks. (2017) (0)
Re: Health spending slowdown is mostly due to economic factors, not structural change in the health care sector. (2015) (0)
Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis. (2019) (0)
PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER (2006) (0)
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. (2017) (0)
COST-EFFECTIVENESS ANALYSIS OF RETREATMENT OF STRESS INCONTINENCE AFTER FAILED SLING WITH EITHER TVT OR PUBOVAGINAL SLING (2011) (0)
Re: Transobturator TVT-O versus retropubic TVT: results of a multicenter randomized controlled trial at 24 months follow-up. (2012) (0)
Sex, Ethnicity, and Variation in the Workup of Hematuria (2014) (0)
Re: Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States. (2016) (0)
Re: Tracking Trends in Provider Reimbursements and Patient Obligations. (2016) (0)
Re: Do men make informed decisions about prostate cancer screening? Baseline results from the "Take the Wheel" trial. (2011) (0)
Re: Public Perceptions of Overlapping Surgery. (2017) (0)
MP31-16 THE IMPACT OF HEALTH LITERACY ON SURGICAL OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2016) (0)
Adherence to therapy for lower urinary tract symptoms: don't mistake association with causation! (2015) (0)
Re: Making Cuts to Medicare: The Views of Patients, Physicians, and the Public. (2015) (0)
447 PRE-TREATMENT DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN A CONTEMPORARY PROSTATE CANCER COHORT: RESULTS FROM CEASAR (2013) (0)
Re: specialty, political affiliation, and perceived social responsibility are associated with U.S. physician reactions to health care reform legislation. (2014) (0)
Re: Patient-to-physician messaging: volume nearly tripled as more patients joined system, but per capita rate plateaued. (2015) (0)
PD30-06 COMPARISON OF EXTERNAL BEAM RADIATION THERAPY AND ROBOTIC PROSTATECTOMY ON PATIENT REPORTED OUTCOMES AFTER 5 YEARS IN MEN WITH UNFAVORABLE INTERMEDIATE-RISK AND HIGH-RISK PROSTATE CANCER (2019) (0)
Editorial comment. (2014) (0)
PD45-07 ASSESSING THE QUALITY OF SURGICAL CARE FOR CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM THE CEASAR STUDY (2019) (0)
Racial variation in the quality of care among patients undergoing cystectomy for bladder cancer (2011) (0)
Quality of life in long-term survivors of bladder cancer (2006) (0)
Laparoscopy and Robotics Biochemical Recurrenceefree Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer (2014) (0)
SOCIODEMOGRAPHIC AND CLINICAL RISK CHARACTERISTICS OF PATIENTS WITH PROSTATE CANCER WITHIN THE VETERANS AFFAIRS HEALTH CARE SYSTEM: DATA FROM C A PSURE (2003) (0)
Editorial Comment. (2016) (0)
Re: A survey analysis suggests that electronic health records will yield revenue gains for some practices and losses for many. (2013) (0)
Re: Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. (2013) (0)
GEOGRAPHIC REGION STRONGLY INFLUENCES TOTAL CHARGES PER PROSTATECTOMY IN THE HCUP-NIS 2004 DATABASE (2009) (0)
74 REGIONAL VARIATION IN PROSTATE CANCER TREATMENT IS NOT CONSISTENT ACROSS AGE GROUPS (2011) (0)
MP60-03 IMPACT OF POST-OPERATIVE COMPLICATIONS AND THE NUMBER OF ‘HOSPITAL-FREE DAYS’ FOLLOWING RADICAL CYSTECTOMY ON QUALITY OF LIFE AT ONE YEAR (2014) (0)
Letters to the Editor/ErrataRE: THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATA (2004) (0)
PCN75 WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT (2007) (0)
Mathematical Issues: PSA Testing (2001) (0)
Re: Satisfaction profiles in men using intracavernosal injection therapy. (2012) (0)
Re: Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. (2012) (0)
Re: Hospitals' Race to Employ Physicians—The Logic Behind a Money-Losing Proposition (2011) (0)
MP67-17 ASSOCIATION BETWEEN TREATMENT FOR LOCALIZED PROSTATE CANCER AND MENTAL HEALTH OUTCOMES (2020) (0)
Re: Measuring low-value care in medicare. (2015) (0)
Re: Changes in health care spending and quality 4 years into global payment. (2015) (0)
Editorial comment. (2014) (0)
Re: increases in consumer cost sharing redirect patient volumes and reduce hospital prices for orthopedic surgery. (2014) (0)
Re: value-based insurance design: quality improvement but no cost savings. (2014) (0)
939 USE OF ROBOTIC ASSISTED RADICAL CYSTECTOMY VERSUS OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER IS ASSOCIATED WITH DECREASED BLOOD LOSS AND PERIOPERATIVE TRANSFUSION RATE (2011) (0)
Capsule Commentary on Shahinian et al.: Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer (2013) (0)
Re: surgical skill and complication rates after bariatric surgery. (2014) (0)
1327: Current Status of Clinical Trials in Urothelial Cancers: A Summary from the ACOSOG Gu Working Group (2005) (0)
Re: Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. (2015) (0)
Re: Do Women With Overactive Bladder Have Realistic Expectations for Therapy? (2011) (0)
Re: Bisphosphonate Prescriptions in Men with Androgen Deprivation Therapy Use. (2015) (0)
Outcomes session. (2012) (0)
MP11-08 THE RELATIONSHIP BETWEEN UROLOGIST SELF-REFERRAL AND SURGICAL TREATMENT FOR URINARY STONE DISEASE (2014) (0)
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? (2022) (0)
Re: The Quality of Care Delivered to Patients within the Same Hospital Varies by Insurance Type (2014) (0)
1656 NATIONAL ASSESSMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PRACTICE PATTERNS: IMMEDIATE POST-OPERATIVE INSTILLATION OF CHEMOTHERAPY (IPOIC) (2011) (0)
Validation of the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer (CRPC): Data from TRUMPET. (2017) (0)
Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now? (2018) (0)
Re: Overtreatment of men with low-risk prostate cancer and significant comorbidity. (2011) (0)
Re: Early Impact of Medicare Accountable Care Organizations on Cancer Surgery Outcomes. (2017) (0)
Re: Cancer Mortality Reductions were Greatest among Countries where Cancer Care Spending Rose the Most, 1995-2007. (2016) (0)
Re: Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies (2016) (0)
Re: Financial Relationships with Industry among National Comprehensive Cancer Network Guideline Authors. (2017) (0)
PREDICTORS OF INTRAVESICAL CHEMOTHERAPY USE IN SUPERFICIAL BLADDER CANCER: RESULTS FROM THE SEER 2003 PATTERNS OF CARE PROJECT (2008) (0)
Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. (2017) (0)
Re: Complementary and Alternative Medicine (CAM) Use in Women With Pelvic Floor Disorders: A Cohort Study. (2011) (0)
A Modest Proposal: Prostate Biopsies and In-house Pathology Laboratories. (2013) (0)
Re: Hospital Closures had No Measurable Impact on Local Hospitalization Rates or Mortality Rates, 2003-11. (2015) (0)
Re: On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim. (2013) (0)
MP5-07 AN EMPIRICAL EVALUATION OF VARIATION IN INTENSITY OF SURVIVORSHIP CARE AND ITS EFFECT ON KIDNEY CANCER-SPECIFIC SURVIVAL (2015) (0)
Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve? (2017) (0)
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
PD03-11 DEFINING PHENOTYPIC “PREFERENCE PROFILES” IN MEN CHOOSING TREATMENT FOR LOCALIZED PROSTATE CANCER (2021) (0)
1757 USE OF PELVIC LYMPHADENECTOMY IN RADICAL CYSTECTOMY FOR BLADDER CANCER: 10-YEAR EXPERIENCE AT A SINGLE INSTITUTION (2012) (0)
Abstract 3628: Benign disease prevalence after surgical lung resection varies geographically in the US Medicare population, implications for lung cancer screening. (2013) (0)
Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer (2017) (0)
Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. (2016) (0)
Financial toxicity and coping mechanisms in patients with metastatic prostate cancer: A pilot study. (2023) (0)
PD31-09 INSTITUTIONAL MODIFICATION OF ANTIBIOTIC PROPHYLAXIS PROTOCOL REDUCES INFECTIOUS COMPLICATIONS FOLLOWING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY (2014) (0)
653 LONG TERM QUALITY OF LIFE OUTCOMES FOLLOWING TREATMENT FOR CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY (2012) (0)
Re: Access to Care and Affordability have Improved following Affordable Care Act Implementation; Problems Remain. (2016) (0)
209: Changing Patterns of Care in Prostate Needle Biopsy in the 1990s among Medicare Beneficiaries (2005) (0)
Reply to M.A.N. Şendur et al and J. Michels. (2017) (0)
Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer. (2017) (0)
Re: Imaging Self-Referral Associated With Higher Costs and Limited Impact on Duration of Illness (2011) (0)
Re: A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment. (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David F. Penson?

David F. Penson is affiliated with the following schools:

University of Pennsylvania
Boston University
McGill University
University of Minnesota
University of Oklahoma Health Sciences Center
University of Southern California
Vanderbilt University
California South Bay University
University of New Mexico
University of Washington

David F. Penson's Academic­Influence.com Rankings

Why Is David F. Penson Influential?

David F. Penson's Published Works

Published Works

What Schools Are Affiliated With David F. Penson?

David F. Penson's AcademicInfluence.com Rankings